Crownmab

Crownmab (Zhejiang Crownmab Biotech Co. Ltd.) is a clinical-stage biotechnology company and a wholly-owned subsidiary of Apollomics, focused on the discovery and development of novel oncology therapies. Based in Hangzhou, China, the company serves as the primary research, development, and manufacturing arm for Apollomics' biologics portfolio in the Greater China region. Crownmab's pipeline features a range of monoclonal and bispecific antibodies targeting immune checkpoints and oncogenic pathways, including its lead PD-1 inhibitor, Genolimzumab. The company also develops targeted small molecules and combination therapies for solid tumors and hematologic malignancies. With integrated capabilities from discovery to clinical development, Crownmab plays a critical role in advancing precision medicine for cancer patients globally.